TLCD3A and prostate cancer: We found that patients with higher expression levels of VPS53 (Log-rank p = 0.03, Figure 7D), FAM57A (Log-rank p = 0.018, Figure 7E), and GEMIN4 (Log-rank p = 0.016, Figure 7F) had worse prostate cancer-specific survival probability.